AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05646238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
Study NCT05646238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training
Description: The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
Study NCT05804227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
Study NCT06229873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Inspiratory Muscle Strength Training
Description: Participants will perform inspiratory muscle strength training guided by a smartphone application. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. All training sessions will be guided by the smartphone application.
Study NCT06229873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-Based Inspiratory Muscle Strength Training
Description: Participants will perform inspiratory muscle strength training guided by researchers. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. One training session each week will be performed in the research clinic.
Study NCT05752266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AMILI Probiotic pills
Description: AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.
Study NCT05766254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 10-Hz TMS to the DLPFC
Description: The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
Study NCT05766254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS-DLPFC
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study NCT05465096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue injection
Description: Intra-articular ultrasound-guided injection of MF-AT
Study NCT05317806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: daily metformin treatment vs. no treatment with metformin
Study NCT06296706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for injection (Albumin-bound)
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
Study NCT06296706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere (docetaxel)
Description: Taxotere, by intravenous infusion, every 3 weeks.
Study NCT06553898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA/CD70 CAR-T cells
Description: Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Study NCT06637670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: 'Y shaped' kinesiology taping was applied on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
Study NCT06637670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo taping
Description: A tape without tension was applied perpendicular on the quadriceps femoris muscle.
Study NCT06168669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: xBar system
Description: xBar system is surgical drain with embedded sensors. Collected data will be evaluated for an ability to identify anastomotic leaks. The xBar system does not have therapeutic indication.
Study NCT04782180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descovy 200Mg 25Mg Tablet
Description: daily Descovy tab by mouth
Study NCT04782180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP
Description: PrEP will be provided in a community setting by community-based harm reduction program.
Study NCT05353751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kind Minds Program
Description: The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude.
Study NCT05353751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kind Minds Program
Description: The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude.
Study NCT04619888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HeartLogic
Description: In case of HeartLogic index ≥16, the investigator will contact the patient to assess the patient's clinical condition and possibly adjust the heart failure treatment. The management will be standardized across centers according to the Manage-HF protocol.
Study NCT06557343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single Cell Sequencing
Description: Sequencing of all viable single cells present in deep bronchial brushings using transcriptomics to identify what cells are present and what they are doing.
Study NCT05752266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.
Study NCT04639037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated adjustment of vasopressor
Description: The objective of this randomized controlled superiority study is to demonstrate that, in patients admitted to intensive care after a major surgery, tight control of MAP using a closed-loop system for vasopressor administration will result in MAP being more often within a MAP range of 80-90 mmHg compared to the same management without this automated closed-loop system (nurse adjustment of vasopressor administration)
Study NCT04639037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual adjustment of vasopressor
Description: Fluid and vasopressor will be delivered as standard of care (manual adjustment of both fluid and vasopressor infusion rate by the nurse)
Study NCT05503680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: In this study, the researcher will provide participants with two month of Hatha yoga as an experimental intervention for managing stress. All participants who belong to the intervention group will be required to complete 120 minutes per week of home-based, online streaming yoga for eight weeks with our certified yoga instructor. The intervention will be conducted online by Zoom video; participants will be sent a link to join a scheduled live online yoga session twice every week. The data collection will be undertaken in three times: baseline (before the intervention begins), posttest one ( after two month intervention), and posttest two (one month after yoga intervention finish) to evaluate the lasting effect of yoga.
Study NCT06231485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS2
Description: One of the two health education curricula as described in arm/group descriptions.
Study NCT06231485 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STYH
Description: One of the two health education curricula as described in arm/group descriptions.
Study NCT04807179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: RF Device Arm
Description: Non-invasive radiofrequency Alexandrite laser
Study NCT05468203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
Study NCT05468203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
Study NCT05029999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD Chemotherapy
Description: PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
Study NCT05029999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
Study NCT05029999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
Study NCT05294523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium priming dose
Description: Add the priming dose of rocuronium after the first supramaximal stimulation data measured
Study NCT05238597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A197 Ophthalmic Solution
Description: A197 Ophthalmic Solution
Study NCT05238597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A197 Vehicle Control
Description: A197 Vehicle Control
Study NCT05238597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Active Comparator
Study NCT05280145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchOpen ultra-portable ultrasound device
Description: Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis
Study NCT05280145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device routinely used in the department
Description: Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis
Study NCT05280145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by an independent referent radiologist
Description: In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
Study NCT05378529 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lp(a) Screening
Description: Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
Study NCT05532657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing intervention
Description: The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
Study NCT05917262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing
Description: The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
Study NCT05917262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
Study NCT05917262 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral pain psychoeducation
Description: The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
Study NCT05532657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successful aging/delayed hearing intervention
Description: The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
Study NCT05445323 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Low dose LX2006
Description: Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Study NCT05445323 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mid Dose LX2006
Description: Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Study NCT05445323 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: High Dose LX2006
Description: Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Study NCT04737603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ED-Initiated treatment with buprenorphine / naloxone
Description: A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores >=8. Participants who weigh > 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
Study NCT05725343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
Study NCT05725343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
Study NCT05434442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: simulation model training
Description: Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator.
Study NCT05434442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mobile app training
Description: An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher.
Study NCT05434442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Clinical routine training will be given to caregivers in this group.
Study NCT05590910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
Study NCT04861064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
Study NCT04860128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports technology application
Description: Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
Study NCT06422026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: APCP I
Description: Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.
Study NCT06422026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: APCP II
Description: Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.
Study NCT06422026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject takes one active bottle per day for 24 weeks.
Study NCT04651348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL95
Description: PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days.
Study NCT04446234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Use medicine according to patients condition
Study NCT04446234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Use medicine according to patients condition
Study NCT04446234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Use medicine according to patients condition
Study NCT04446234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Use medicine according to patients condition
Study NCT04446234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Use medicine according to patients condition
Study NCT06554301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin in treatment pulmonary aerterial hypertension
Description: On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
Study NCT06554301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in treatment pulmonary aerterial hypertension
Description: On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
Study NCT05859555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thematic quality circles - Deprescription
Description: Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)